The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated 
with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272.

Minami, Y.; Shimamura, T.; Shah, Kinjal; Laframboise, Thomas; Glatt, Karen A.; Liniker, E.; Borgman, C.L.; Haringsma, H.J.; Feng, W.; Weir, B.A.; Lowell, A.M.; Lee, J. C.; Wolf, Jürgen; Shapiro, G.I.; Wong, Kwok-Kin; Meyerson, Matthew; Thomas, Roman K.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272.

MPS-Authors

/persons/resource/persons147315

Thomas, Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Minami, Y., Shimamura, T., Shah, K., Laframboise, T., Glatt, K. A., Liniker, E., et al. (2007). The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272. Oncogene, 26(34), 5023-5027.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-D9FF-3

Abstract

There is no abstract available